Vaxcell-Bio Therapeutics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	7,821	9,046	389.66	2,309	9,903
Short-Term Investments	28,234	41,000	20,002	25,000	9,000
Cash & Short-Term Investments	36,055	50,046	20,392	27,309	18,903
Cash Growth	-27.96%	145.42%	-25.33%	44.47%	134.10%
Accounts Receivable	956.33	0.08	-	-	-
Other Receivables	916.3	581.97	210.31	353.21	96.63
Receivables	1,973	582.05	210.31	353.21	96.63
Inventory	237.79	96.74	-	-	-
Prepaid Expenses	548.58	185.45	190.31	504.84	70.66
Other Current Assets	291.31	316.92	105.7	30.62	116.37
Total Current Assets	39,105	51,227	20,898	28,197	19,186
Property, Plant & Equipment	6,509	2,674	2,541	2,804	1,142
Long-Term Investments	24,920	29,873	-0	-0	15,000
Goodwill	2,449	-	-	-	-
Other Intangible Assets	2,341	206.65	229.46	147.62	68.82
Long-Term Accounts Receivable	17.47	-	-	-	-
Other Long-Term Assets	1,603	999.18	494.03	126.87	100.88
Total Assets	76,944	84,980	24,163	31,276	35,498
Accounts Payable	478.43	-	-	-	-
Accrued Expenses	225.79	117.87	118.23	129.42	188.94
Current Portion of Leases	865.42	216.89	46.51	183.05	186.36
Other Current Liabilities	1,251	589.38	142.3	79.84	218.89
Total Current Liabilities	2,820	924.14	307.04	392.3	594.19
Long-Term Leases	1,403	144.34	58.72	37.39	152.75
Other Long-Term Liabilities	726.99	269.63	219.11	112.64	20.84
Total Liabilities	4,950	1,487	835.78	1,196	830.1
Common Stock	11,497	11,497	7,612	7,612	3,762
Additional Paid-In Capital	115,619	115,619	48,888	48,888	51,913
Retained Earnings	-54,413	-43,537	-33,383	-26,505	-21,288
Treasury Stock	-1,365	-532.7	-	-	-
Comprehensive Income & Other	656.25	447.51	210.35	85.39	280.14
Total Common Equity	71,994	83,493	23,327	30,080	34,667
Shareholders' Equity	71,994	83,493	23,327	30,080	34,667
Total Liabilities & Equity	76,944	84,980	24,163	31,276	35,498
Total Debt	2,268	361.23	105.24	220.44	339.11
Net Cash (Debt)	33,787	49,685	20,287	27,088	18,563
Net Cash Growth	-32.00%	144.91%	-25.11%	45.92%	143.91%
Net Cash Per Share	1472.50	2534.04	1332.65	1791.57	2725.80
Filing Date Shares Outstanding	22.93	22.96	18.27	18.27	9.03
Total Common Shares Outstanding	22.93	22.96	18.27	18.27	9.03
Working Capital	36,285	50,303	20,591	27,805	18,592
Book Value Per Share	3140.35	3635.75	1276.97	1646.65	3840.16
Tangible Book Value	67,204	83,287	23,098	29,933	34,599
Tangible Book Value Per Share	2931.41	3626.75	1264.41	1638.57	3832.54
Land	1,647	1,602	1,602	1,602	-
Machinery	4,426	2,489	2,346	2,213	1,717
Construction In Progress	241.8	22.51	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.